ArriVent BioPharma, Inc. (AVBP) vs Hemab Therapeutics Holdings, Inc. Common Stock (COAG)
A side-by-side comparison of ArriVent BioPharma, Inc. and Hemab Therapeutics Holdings, Inc. Common Stock across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AVBP
ArriVent BioPharma, Inc.
$28.46HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
COAG
Hemab Therapeutics Holdings, Inc. Common Stock
$30.59HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
Total return — AVBP vs COAG
growth of $100 · dividends reinvested · last 1yAVBP -5.1% (-5.1%/yr)COAG -10.0% (-10.0%/yr)AVBP compounded faster over this window
AVBP COAG
AVBP vs COAG: by the numbers
- •COAG is the larger company ($1.43B vs $1.33B market cap).
Metrics side by side
Valuation
| Metric | AVBP | COAG |
|---|---|---|
| P/B ratio | 3.61 | 3.15 |
Profitability
| Metric | AVBP | COAG |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -44.63% | N/A |
| ROIC | -47.96% | -38.09% |
Go deeper
Dig into the metrics
ArriVent BioPharma ROEHemab Therapeutics Holdings, Inc. Common Stock ROEArriVent BioPharma operating marginHemab Therapeutics Holdings, Inc. Common Stock operating marginArriVent BioPharma revenue growthHemab Therapeutics Holdings, Inc. Common Stock revenue growthArriVent BioPharma free cash flowHemab Therapeutics Holdings, Inc. Common Stock free cash flow
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.